Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 150 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Exelixis Clear all

Conditions: Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis
Interventions: XL495, ADC cytotoxic agents; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more

Conditions: Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: XL092, Pembrolizumab; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia • Chapel Hill, North Carolina • Philadelphia, Pennsylvania

Conditions: Hepatocellular Carcinoma, Liver Cancer
Interventions: Durvalumab, Zanzalintinib; Drug
Lead sponsor: Amit Mahipal; Other
Eligibility: 19 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
Interventions: XB010, Pembrolizumab; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more

Conditions: Advanced Cancer, Various, NOS
Interventions: BMS-833923, Lenalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 5 more

Conditions: Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
Interventions: Nivolumab, Cabozantinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer, Persistent Cervical Cancer
Interventions: Cabozantinib 40 MG oral once a day, Pembrolizumab 200 mg IV every 3 weeks; Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Healthy, Renal Impairment
Interventions: cabozantinib; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Neptune City, New Jersey

Conditions: Colorectal Cancer
Interventions: Panitumumab, Cabozantinib; Biological · Drug
Lead sponsor: John Strickler, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cancer, Solid Tumors
Interventions: XL418; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 2
States / cities: Detroit, Michigan • San Antonio, Texas

Conditions: Polycythemia Vera
Interventions: XL019; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 2 more

Conditions: Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities
Interventions: Cabozantinib S-malate, Radiation Therapy; Drug · Radiation
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pancreatic Adenocarcinoma Metastatic
Interventions: Cabozantinib 40 MG, Erlotinib 100Mg Tab; Drug
Lead sponsor: Patrick Joseph Loehrer Sr.; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Cabozantinib; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
Interventions: Abemaciclib, Cabozantinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Baltimore, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions: cabozantinib, atezolizumab; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 57
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Cabozantinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cancer, Non-small-cell Lung Cancer, Breast Cancer
Interventions: XL647, XL147; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: New York, New York • San Antonio, Texas

Conditions: Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions: XL228; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more

Conditions: Medullary Thyroid Cancer
Interventions: cabozantinib; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
U.S. locations: 5
States / cities: Stanford, California • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Advanced Solid Cancers, Metastatic Cancer
Interventions: Cdc7-inhibitor; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Meningioma
Interventions: Zanzalintinib; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 17 more

Conditions: Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
Interventions: XL092, Atezolizumab, Avelumab; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 40
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 33 more

Conditions: Metastatic Hormone Refractory Prostate Cancer
Interventions: Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

Study of XB010 in Subjects With Solid Tumors

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Cabozantinib and Nivolumab for Carcinoid Tumors

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer

Study of XL418 in Adults With Solid Tumors

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)